Jun 2026 (Q2 FY26) — Aug 6, 2026
Artivion Q2 FY26 — Strong Growth, Key Approvals, and Strategic Acquisitions Drive Momentum
Read the full callArtivion (AORT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Artivion earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 126 | +11.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -6.7 | −14.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -13.5 | −1104.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$22.28 +2.30% · +$0.5
Performance −47.1% 1Y
1Y: $42.08 on 17 Oct 2025 → $22.28. High $47.63 (12 Nov 2025), low $20.1 (12 Jun 2026).
- Previous close
- $21.78
- 52-week range
- $20.1 – $47.63
- One year
- −47.71%
Overview
- Symbol
- AORT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Artivion earnings calls (AORT)
Financials
What the filings say
Net profit, year on year: −1104% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 96 | 97 | 99 | 113 | 113 | 116 | 116 | 126 |
| Operating profit | 4 | 3 | 2 | 8 | 13 | 11 | 6 | -8 |
| Operating margin | 4.6% | 2.7% | 2.2% | 7.4% | 11.1% | 9.2% | 5.0% | −6.7% |
| Interest | 8 | 10 | 8 | 7 | 6 | 6 | 5 | 7 |
| Profit before tax | -1 | -17 | -2 | 3 | 7 | 7 | 0 | -12 |
| Tax rate | −80.7% | 0.7% | 78.0% | 61.4% | 7.8% | 62.9% | −318.0% | −15.5% |
| Net profit | -2 | -16 | -1 | 1 | 7 | 2 | 1 | -14 |
| EPS ($ per share) | -0.05 | — | -0.01 | 0.03 | 0.14 | — | 0.03 | -0.28 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 35 | 37 | 20 | 2 | -17 | -48 | -61 | -51 |
| Total liabilities | 296 | 320 | 461 | 492 | 478 | 511 | 513 | 437 |
| Fixed assets | 31 | 32 | 33 | 38 | 39 | 38 | 36 | 65 |
| Total assets | 571 | 606 | 789 | 793 | 763 | 792 | 789 | 885 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 10 | 16 | 12 | -3 | -5 | 19 | 22 | 40 |
| Cash from investing | -7 | -24 | -73 | 6 | -11 | -1 | -28 | -42 |
| Cash from financing | -3 | -1 | 94 | -12 | -2 | 1 | 2 | 11 |
| Net cash flow | 1 | -8 | 28 | -7 | -16 | 20 | -5 | 11 |
| Capital expenditure | -6 | -8 | -7 | -13 | -11 | -10 | -11 | -39 |
| Free cash flow | 4 | 8 | 5 | -16 | -16 | 9 | 11 | 1 |
Insider filings
100 filings between Nov 10, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$20.73M
64 sales by 8 insiders
13% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
- 13
- Option exercise — converted options into shares
Also filed: 2 other filings, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Mackin James P | — | $9.72M | Aug 19, 2026 |
| Stanton Marshall S. | — | $3.43M | Mar 3, 2026 |
| Holloway Jean F | — | $2.54M | Aug 12, 2026 |
| Davis John E | — | $1.75M | Mar 3, 2026 |
| GREEN ANDREW M | — | $1.43M | Sep 10, 2026 |
| Horton Amy | — | $870.1K | Mar 3, 2026 |
| Berry Lance A | — | $803.2K | Aug 14, 2026 |
| Hoff Elizabeth A | — | $189.4K | Nov 18, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale | 11,480 | $286.7K |
| Sep 3, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale | 1,493 | $38.8K |
| Sep 2, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale | 6,510 | $177.5K |
| Aug 19, 2026 | Mackin James P President & CEO | Sale | 70,000 | $2.03M |
| Aug 14, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale | 616 | $17.6K |
| Aug 14, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 715 | $20.4K |
| Aug 12, 2026 | Holloway Jean F SVP, General Counsel | Sale | 977 | $27.8K |
| Jun 11, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale 10b5-1 plan | 14,001 | $289.9K |
| Jun 11, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Sale 10b5-1 plan | 30,000 | $620.8K |
| Jun 11, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Option exercise 10b5-1 plan | 14,001 | $258.2K |
| Jun 11, 2026 | GREEN ANDREW M SVP, Regulatory and Quality | Option exercise 10b5-1 plan | 30,000 | $330.9K |
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | $0 |
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | $0 |
| May 18, 2026 | Hoff Elizabeth A Director | Award | 7,576 | $0 |
| May 18, 2026 | Salveson Jon W Director | Award | 7,576 | $0 |
| May 18, 2026 | Bullock James Director | Award | 7,576 | $0 |
| May 18, 2026 | Borgstrom Marna P Director | Award | 7,576 | $0 |
| May 18, 2026 | SEMEDO ANTHONY B. Director | Award | 7,576 | $0 |
| May 18, 2026 | BEVEVINO DANIEL J Director | Award | 7,576 | $0 |
| May 18, 2026 | ACKERMAN THOMAS F Director | Award | 7,576 | $0 |
| May 18, 2026 | Burbank Jeffrey H Director | Award | 7,576 | $0 |
| May 14, 2026 | Borgstrom Marna P Director | Award | 7,850 | $0 |
| Mar 4, 2026 | Holloway Jean F SVP, General Counsel | Sale | 8,962 | $340.6K |
| Mar 3, 2026 | Holloway Jean F SVP, General Counsel | Sale | 3,843 | $145.2K |
| Mar 3, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 2,149 | $81.2K |
| Mar 3, 2026 | Davis John E Chief Commercial Officer | Sale | 4,573 | $172.7K |
| Mar 3, 2026 | Mackin James P President & CEO | Sale | 17,887 | $675.7K |
| Mar 3, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 6,316 | $238.6K |
| Mar 3, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 901 | $34.0K |
| Mar 2, 2026 | Holloway Jean F SVP, General Counsel | Award | 27,795 | $0 |
| Mar 2, 2026 | Davis John E Chief Commercial Officer | Award | 28,845 | $0 |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Award | 21,838 | $0 |
| Mar 2, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Award | 40,874 | $0 |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Award | 7,475 | $0 |
| Mar 2, 2026 | Mackin James P President & CEO | Award | 116,948 | $0 |
| Mar 2, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 5,178 | $196.9K |
| Mar 2, 2026 | Davis John E Chief Commercial Officer | Sale | 2,784 | $105.9K |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 641 | $24.4K |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 1,513 | $57.5K |
| Mar 2, 2026 | Mackin James P President & CEO | Sale | 14,911 | $567.0K |
| Mar 2, 2026 | Holloway Jean F SVP, General Counsel | Sale | 2,183 | $83.0K |
| Feb 24, 2026 | Holloway Jean F SVP, General Counsel | Sale | 1,668 | $59.5K |
| Feb 24, 2026 | Mackin James P President & CEO | Award | 97,030 | $0 |
| Feb 24, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 830 | $29.6K |
| Feb 24, 2026 | Mackin James P President & CEO | Sale | 13,936 | $497.4K |
| Feb 24, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 4,485 | $160.1K |
| Feb 24, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Award | 37,482 | $0 |
| Feb 24, 2026 | Davis John E Chief Commercial Officer | Sale | 2,075 | $74.1K |
| Feb 24, 2026 | Davis John E Chief Commercial Officer | Award | 20,438 | $0 |
| Feb 24, 2026 | Holloway Jean F SVP, General Counsel | Award | 20,085 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ARTIVION, INC.
Free account. Everything above stays public.
Write why you follow ARTIVION, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading